Top Story

Liraglutide improves weight, HbA1c in overweight/obese adults with type 2 diabetes

March 5, 2015

SAN DIEGO — More patients with overweight and obesity achieved clinically meaningful weight loss with liraglutide 3 mg and 1.8 mg compared with placebo, according to research presented here.

Patients who responded to liraglutide (Saxenda, Victoza; Novo Nordisk) achieved a total weight loss of approximately 10% and greater improvements in HbA1c, suggesting an additional treatment benefit, with the rates of adverse events similar at both doses.

Peter Clayton Meeting News Coverage

Summer daylight exposure linked to growth in GH-deficient children

March 5, 2015
SAN DIEGO — Genes modulating growth and summer daylight exposure are subject to a complex gene–environment interaction in response to recombinant human…
Meeting News Coverage

Subclinical thyroid disease increased mortality risk in older adults

March 5, 2015
SAN DIEGO — Risk for mortality in older adults increased with diagnoses of subclinical hypothyroidism or subclinical hyperthyroidism, according to study findings…
Meeting News Coverage

Estimated cost burden of EDC exposure 'staggering' in EU, translates to US

March 5, 2015
SAN DIEGO — Exposure to endocrine-disrupting chemicals could cost the European Union as much as €157 billion, or $209 billion, per year in health care…
Ruchi Mathur Meeting News Coverage

Intestinal gases after bariatric surgery may predict less weight loss

March 5, 2015
SAN DIEGO — After bariatric surgery, patients with gastrointestinal methanogen colonization — assessed by measuring methane and hydrogen in the breath…
More News Headlines »
low no

Low- and No-Calorie Sweeteners in Weight Management: What Do You Need to Know?

This activity is supported by an educational grant from the American Beverage Association.

The use of low- and no-calorie sweeteners continues to grow as consumers continue to purchase foods and beverages…
More »
Meeting News Coverage Video
Hatipoglu th

Autologous islet cell transplantation effective for chronic pancreatitis

December 3, 2014
In this video exclusive, Betul Hatipoglu, MD, clinical associate professor of medicine of the Endocrinology &…
More »
Obesity Consults: Volume 2, Number 2 Obesity Forum 2014 Highlights

Obesity Consults: Volume 2, Number 2
Obesity Forum 2014 Highlights

This activity is supported by educational grants from Takeda Pharmaceuticals International, Inc., US Region and Orexigen Therapeutics, Inc; Eisai, Inc.; Novo Nordisk; Vivus, Inc.

Management of obesity is complex, factoring in psychological, environmental, and physiologic causes. Treatment options…
More »
Current Issues
View the Current Issues